Back Hepatitis C

Hepatitis C

APASL: Simeprevir Matches Telaprevir in Phase 3 Study, Gets Positive European Regulatory Opinion

The new hepatitis C virus (HCV) protease inhibitor simeprevir has received a positive opinion from the Committee for Medicinal Products for Human Use (CHMP), recommending marketing authorization in the European Union, Janssen R&D announced this week. The recommendation was based on findings from a set of Phase 3 trials, some of which were presented at the Asian Pacific Association for the Study of the Liver (APASL) conference this month in Brisbane.

alt

Advances in Hepatitis C Treatment: the Future Is Now [VIDEO]

As effective direct-acting antiviral drugs to treat hepatitis C come into widespread use and interferon-free therapy becomes a reality, patients, providers, and payers are now grappling with issues such as who should receive treatment and how to pay for the new medications.

alt

Hepatitis C Liver Decompensation Remains a Problem for People with HIV Despite Good ART

People with HIV who are coinfected with hepatitis C virus (HCV) continue to have a higher risk for decompensated cirrhosis, or liver failure, even in the era of effective antiretroviral therapy (ART), according to a study published in the March 18 Annals of Internal Medicine. As such, they especially stand to benefit from new interferon-free hepatitis C treatments.

alt

CROI 2014: Interferon-free BMS Combo Cures 90% of Genotype 1 Hepatitis C

An all-oral regimen of daclatasvir, asunaprevir, and BMS-791325 -- without interferon or ribavirin -- led to sustained response in approximately 90% of previously untreated hepatitis C patients, most with hard-to-treat genotype 1a, according to a study presented at the 21st Conference on Retroviruses and Opportunistic Infections (CROI 2014) this month in Boston.

alt

New U.S. Hepatitis C Survey Suggests Lower Prevalence, Higher Mortality

An estimated 2.7 million people in the U.S. have chronic hepatitis C, substantially lower than previous estimates, according to an analysis from the National Health and Nutrition Examination Survey(NHANES) published in the March 4 edition of Annals of Internal Medicine. This figure may be an underestimate, however, as the household survey does not include higher-risk populations including homeless and incarcerated people.

alt

CROI 2014/APASL 2014: Merck Combo Suppresses HCV in Monoinfected and Coinfected Patients

An all-oral combination of the HCV protease inhibitor MK-5172 and the NS5A inhibitor MK-8742, with or without ribavirin, demonstrated promising end-of-treatment viral suppression in HIV/HCV coinfected patients and high cure rates in people with hepatitis C alone, according to findings from the C-WORTHY study presented at recent conferences.

alt

CROI 2014: Daclatasvir + Simeprevir Effective Against Hepatitis C Genotype 1b

An all-oral regimen of daclatasvir plus simeprevir, without interferon or ribavirin, led to sustained response in 85% to 95% of patients with hepatitis C genotype 1b, but this combination did not work well against genotype 1a, researchers reported last week at the 21st Conference on Retroviruses and Opportunistic Infections (CROI 2014) in Boston.

alt

APASL 2014: Latest Hepatitis C Treatments Offer Good News for HIV/HCV Coinfected People

People coinfected with HIV and hepatitis C are at risk of faster liver disease progression, so they stand to benefit even more from new direct-acting antiviral therapies that could cure hepatitis C as effectively and be equally well-tolerated in HIV/HCV coinfected and HCV monoinfected patients, Gregory Dore said at the 23rd Conference of the Asian Pacific Association for the Study of the Liver (APASL 2014) last week in Brisbane.

alt

CROI 2014: Simeprevir Cures Almost 80% of First-time HIV/HCV Coinfected Patients

The next-generation hepatitis C protease inhibitor simeprevir (Olysio) cured nearly 80% of previously untreated people with hepatitis C and HIV coinfection when used in combination with pegylated interferon and ribavirin, Douglas Dieterich of Mt. Sinai Medical Center reported on Tuesday at the 21st Conference on Retroviruses and Opportunistic Infections (CROI 2014) in Boston.

alt